Therapy prediction and optimization for renal failure blood therapy

1. A dialysis therapy system comprising:

a memory device storing an estimated dialysis therapy patient parameter for a patient including at least one of (i) an inter-compartmental diffusion coefficient of the patient; (ii) a mobilization clearance of the patient; (iii) a distribution volume of a blood solute in the patient; (iv) a generation rate of a blood solute; (v) a perfused or extracellular volume of the patient; (vi) a non-perfused or intracellular volume of the patient, (vii) an extracellular concentration of a blood solute, or (viii) an intracellular concentration of a blood solute; and

a processor communicatively coupled to the memory device and configured to

receive a therapy prescription for a patient, the therapy prescription having at least one dialysis input value that specifies a dialysis treatment to be performed by a dialysis machine,

determine a predicted blood solute concentration of the patient based on the therapy prescription and the at least one dialysis patient parameter stored in the memory device,

receive data related to a measured blood solute concentration of the patient during or after the dialysis treatment that is performed according to the therapy prescription,

compare the measured blood solute concentration to the predicted blood solute concentration for the selected therapy prescription,

cause a display device communicatively coupled to the processor to show information indicative of the comparison of the measured blood solute concentration to the predicted blood solute concentration for determining whether the therapy prescription is to be changed,

receive from an input device communicatively coupled to the processor, a change to at least one of the dialysis input values of the therapy prescription to create a changed therapy prescription, and

transmit the changed therapy prescription for a subsequent dialysis treatment performed by the dialysis machine.

2. The system of claim 1 , wherein the information indicative of the comparison of the measured blood solute concentration to the predicted blood solute concentration includes an indication as to whether the therapy prescription is to be changed.

3. The system of claim 1 , wherein the processor is configured to transmit the changed therapy prescription to the dialysis machine via a network connection to cause the dialysis machine to perform the subsequent dialysis treatment using the at least one dialysis input value from the changed therapy prescription.

4. The system of claim 1 , wherein the received data related to the blood solute concentration of the patient is determined from a test of the patient's blood that is collected during the dialysis treatment.

5. The system of claim 1 , wherein the data related to a measured blood solute concentration is received in the processor from the input device or is received in the processor via a network connection with the dialysis machine.

6. The system of claim 1 , wherein the predicted concentration includes a time-based prediction of blood solute concentration values that are estimated for at least one of a duration or a frequency of the dialysis treatment.

7. The system of claim 1 , wherein the processor is configured to:

receive a pre-dialytic body weight value and a post-dialytic body weight value of the patient;

determine an ultrafiltration rate as a difference between the pre-dialytic body weight value and the post-dialytic body weight value that is divided by a total treatment time during a session of the dialysis treatment;

estimate at least one of a mobilization clearance of the patient or a pre-dialysis distribution volume of the blood solute of the patient using at least the ultrafiltration rate; and

predict blood solute concentration values of the patient for a remainder of the dialysis treatment using the at least one of the estimated mobilization clearance of the patient or the pre-dialysis distribution volume of the blood solute of the patient.

8. The system of claim 7 , wherein the processor is configured to:

compare the predicted blood solute concentration values of the patient for the remainder of the dialysis treatment to the predicted blood solute concentration for the selected therapy prescription;

cause the display device to show the comparison of the predicted blood solute concentration values of the patient for the remainder of the dialysis treatment to the predicted blood solute concentration for the selected therapy prescription as the recommendation or as a second recommendation as to whether the therapy prescription is to be changed;

receive from the input device, the change or a second change to at least one of the dialysis input values of the therapy prescription to create the changed therapy prescription or a second changed therapy prescription; and

transmit the changed therapy prescription or the second changed therapy prescription for the subsequent dialysis treatment performed by the dialysis machine.

9. The system of claim 1 , wherein the at least one dialysis input value of the therapy prescription includes at least one of a treatment duration, a treatment frequency, a blood flowrate, a dialysate flowrate, a dialysis total volume, an ultrafiltration flowrate, and an ultrafiltration volume.

10. The system of claim 1 , wherein the blood solute includes at least one of urea concentration, beta 2-microglobulin (“β2-M”), or phosphate.

11. The system of claim 1 , wherein the dialysis treatment includes at least one of a hemodialysis treatment, a hemofiltration treatment, a hemodiafiltration treatment, a peritoneal dialysis treatment, or a continuous renal replacement therapy (“CRRT”) treatment.

12. A renal failure blood therapy system comprising:

a renal failure blood therapy machine configured to administer a renal failure blood treatment to a patient according to a therapy prescription including at least one parameter selected for a treatment duration, a treatment frequency, a blood flowrate, a dialysate flowrate, a dialysis total volume, an ultrafiltration flowrate, and an ultrafiltration volume; and

a computing device communicatively coupled to the renal failure blood therapy machine and configured to

determine or identify the therapy prescription administered to the patient,

determine or identify a predicted blood solute concentration of the patient based on the selected therapy prescription and at least one renal failure blood therapy patient parameter,

receive data related to a measured blood solute concentration during or after the renal failure blood treatment performed according to the therapy prescription,

compare the measured blood solute concentration to the predicted blood solute concentration,

display results from the comparison of the measured blood solute concentration to the predicted blood solute concentration for determining whether the therapy prescription is to be changed,

receive a change to at least one of the parameters of the therapy prescription to create a changed therapy prescription, and

transmit the changed therapy prescription to the renal failure blood therapy machine for a subsequent renal failure blood treatment.

13. The system of claim 12 , wherein the information indicative of the comparison of the measured blood solute concentration to the predicted blood solute concentration includes a recommendation as to whether the therapy prescription is to be changed.

14. The system of claim 12 , wherein the at least one renal failure blood therapy patient parameter includes at least one of (i) an inter-compartmental diffusion coefficient of the patient; (ii) a mobilization clearance of the patient; (iii) a distribution volume of a blood solute in the patient; (iv) a generation rate of a blood solute; (v) a perfused or extracellular volume of the patient; (vi) a non-perfused or intracellular volume of the patient, (vii) an extracellular concentration of a blood solute, or (viii) an intracellular concentration of a blood solute.

15. The system of claim 14 , wherein the at least one renal failure blood therapy patient parameter is stored in a memory device that is communicatively coupled to the computing device.

16. The system of claim 12 , wherein the computing device includes at least one of a handheld client device, a personal computer client device, or a server.

17. The system of claim 12 , wherein the blood solute includes at least one of urea concentration, beta 2-microglobulin (“β2-M”), or phosphate, and

wherein the renal failure blood treatment includes at least one of a hemodialysis treatment, a hemofiltration treatment, a hemodiafiltration treatment, or a continuous renal replacement therapy (“CRRT”) treatment.

18. The system of claim 12 , wherein the computing device is configured to:

receive a pre-dialytic body weight value and a post-dialytic body weight value of the patient;

determine an ultrafiltration rate as a difference between the pre-dialytic body weight value and the post-dialytic body weight value that is divided by a total treatment time during a session of the renal failure blood treatment;

estimate at least one of a mobilization clearance of the patient or a pre-renal failure blood treatment distribution volume of the blood solute of the patient using at least the ultrafiltration rate; and

predict blood solute concentration values of the patient for a remainder of the renal failure blood treatment using the at least one of the estimated mobilization clearance of the patient or the pre-renal failure blood treatment distribution volume of the blood solute of the patient.

19. The system of claim 18 , wherein the computing device is configured to:

compare the predicted blood solute concentration values of the patient for the remainder of the renal failure blood treatment to the predicted blood solute concentration for the selected therapy prescription;

cause the display device to show the comparison of the predicted blood solute concentration values of the patient for the remainder of the renal failure blood treatment to the predicted blood solute concentration for the selected therapy prescription as the recommendation or as a second recommendation as to whether the therapy prescription is to be changed;

receive the change or a second change to at least one of the parameters of the therapy prescription to create the changed therapy prescription or a second changed therapy prescription; and

transmit the changed therapy prescription or the second changed therapy prescription to the renal failure blood therapy machine for the subsequent renal failure blood treatment.

20. A renal failure blood therapy method comprising:

storing, via a processor to a memory device, an estimated renal failure blood therapy patient parameter for a patient including at least one of (i) an inter-compartmental diffusion coefficient of the patient; (ii) a mobilization clearance of the patient; (iii) a distribution volume of a blood solute in the patient; (iv) a generation rate of a blood solute; (v) a perfused or extracellular volume of the patient; (vi) a non-perfused or intracellular volume of the patient, (vii) an extracellular concentration of a blood solute, or (viii) an intracellular concentration of a blood solute;

determining, in the processor, a therapy prescription including at least one dialysis parameter selected for a renal failure blood treatment to be performed by a renal failure blood therapy machine;

determining, in the processor, a predicted blood solute concentration of the patient based on the therapy prescription and the at least one renal failure blood therapy patient parameter stored in the memory device;

receiving, in the processor, data related to a measured blood solute concentration of the patient during or after the renal failure blood treatment performed according to the therapy prescription;

comparing, via the processor, the measured blood solute concentration to the predicted blood solute concentration;

displaying, via a display device communicatively coupled to the processor, information indicative of the comparison of the measured blood solute concentration to the predicted blood solute concentration for determining whether the therapy prescription is to be changed;

receiving, in the processor, a change to at least one of the parameters of the therapy prescription to create a changed therapy prescription; and

transmitting, from the processor, the changed therapy prescription to the renal failure blood therapy machine for a subsequent renal failure blood treatment.

21. The method of claim 20 , wherein the information indicative of the comparison of the measured blood solute concentration to the predicted blood solute concentration includes a recommendation as to whether the therapy prescription is to be changed.

22. The method of claim 20 , wherein the blood solute includes at least one of urea concentration, beta 2-microglobulin (“β2-M”), or phosphate, and

wherein the renal failure blood treatment includes at least one of a hemodialysis treatment, a hemofiltration treatment, a hemodiafiltration treatment, or a continuous renal replacement therapy (“CRRT”) treatment.

23. The method of claim 20 , further comprising:

receiving in the processor, a pre-dialytic body weight value and a post-dialytic body weight value of the patient;

determining, via the processor, an ultrafiltration rate as a difference between the pre-dialytic body weight value and the post-dialytic body weight value that is divided by a total treatment time during a session of the renal failure blood treatment;

estimating, via the processor, at least one of a mobilization clearance of the patient or a pre-renal failure blood treatment distribution volume of the blood solute of the patient using at least the ultrafiltration rate; and

predicting, via the processor, blood solute concentration values of the patient for a remainder of the renal failure blood treatment using the at least one of the estimated mobilization clearance of the patient or the pre-renal failure blood treatment distribution volume of the blood solute of the patient.

24. The method of claim 23 , further comprising:

comparing, via the processor, the predicted blood solute concentration values of the patient for the remainder of the renal failure blood treatment to the predicted blood solute concentration for the selected therapy prescription;

displaying, via the display device, information that is indicative of the comparison of the predicted blood solute concentration values of the patient for the remainder of the renal failure blood treatment to the predicted blood solute concentration for the selected therapy prescription as the recommendation or as a second recommendation as to whether the therapy prescription is to be changed;

receiving, in the processor, the change or a second change to at least one of the parameters of the therapy prescription to create the changed therapy prescription or a second changed therapy prescription; and

transmitting, from the processor, the changed therapy prescription or the second changed therapy prescription to the renal failure blood therapy machine for the subsequent renal failure blood treatment.